Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 22 clinical trials
Featured trial
  • 372 views
  • 23 Nov, 2020
  • 1 location
Featured trial
An Exploratory Study to Evaluate the Safety and Efficacy of Secukinumab in the Treatment of Extensive Alopecia Areata

An Exploratory Study to Evaluate the Safety and Efficacy of Secukinumab in the Treatment of Extensive Alopecia Areata

  • 2303 views
  • 23 Nov, 2020
  • 1 location
Featured trial
A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in

  • 2367 views
  • 23 Nov, 2020
  • 18 locations
Featured trial
Acne, psoriasis, atopic dermatitis

Acne, psoriasis, atopic dermatitis

  • 1950 views
  • 25 Mar, 2021
  • 1 location
None
Therapeutic Drug Monitoring of Secukinumab in Psoriasis Patients.

Biologics such as secukinumab are currently the most effective treatment option for patients with moderate to severe psoriasis. But they are costly for healthcare systems and still described

psoriasis
biologics
  • 0 views
  • 26 Jan, 2021
  • 7 locations
None
Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT).

This is a phase IV, single-center, open label, single arm study in which a group of 30 subjects with moderate to severe plaque psoriasis will receive secukinumab therapy. Non-invasive imaging

secukinumab therapy
psoriasis
oophorectomy
tuberculin purified protein derivative
prophylaxis
  • 22 views
  • 11 Sep, 2021
  • 1 location
None
AScalate: Treat-to-target in Axial Spondyloarthritis

secukinumab as first-line biologic) is superior to a Standard-Of-Care (SOC) approach in terms of achieving strong clinical efficacy in patients with active axial Spondyloarthritis (axSpA) who are nave to

spondylitis
NSAID
secukinumab
adalimumab
biological therapy
  • 1 views
  • 25 Aug, 2021
  • 44 locations
None
Secukinumab Open Label Roll-over Extension Protocol

The purpose of this study is to assess long term safety in participants who have completed a Novartis trial with secukinumab, have been judged by the investigator to benefit from continued

  • 0 views
  • 08 Sep, 2021
  • 30 locations
None
Study to Demonstrate the Efficacy Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA

The purpose of this global study is to demonstrate the efficacy, safety, and tolerability of an intravenous (i.v.) regimen of secukinumab compared to placebo in subjects with active axSpA at

  • 85 views
  • 27 Aug, 2021
  • 110 locations
None
Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa

regimens and to assess long-term efficacy, safety and tolerability of secukinumab in subjects with moderate to severe hidradenitis suppurativa completing either of the 2 Phase III studies. This is an

expanded access trial
secukinumab
hidradenitis
  • 75 views
  • 26 Aug, 2021
  • 171 locations